CA-9

We have a program researching the potential of our technology with the antigen AntigenA substance that causes the body's immune system to react. This reaction often involves production of antibodies. For example, the immune system's response to antigens that are part of bacteria and viruses helps people resist infections. Cancer cells have certain antigens that can be found by laboratory tests. They are important in cancer diagnosis and in watching response to treatment. Other cancer cell antigens play a role in immune reactions that may help the body's resistance against cancer. Closecarbonic anhydrase IX (CA9). CA9 is present on approximately 75 percent of cervical and colon cancers and 95 percent of renal cancers.

In May 2006, researchers presented preclinical data demonstrating that active cellular immunotherapy using our proprietary Antigen Delivery Cassette™ Antigen Delivery Cassetteā„¢Dendreon's proprietary approach for antigen modification. The cassette allows for the engineering or modification of tumor antigens to augment the uptake and processing of the antigen by dendritic cells to increase the potency of an immune response.Closetechnology with the antigen CA9 significantly prolonged survival in renal cell carcinoma animal models. CA9 also holds potential for studies in colon and cervical cancer. CancerCancer develops when cells in the body begin to grow out of control. Normal cells grow, divide, and die. Instead of dying, cancer cells continue to grow and form new abnormal cells. Cancer cells often travel to other body parts where they grow and replace normal tissue. This spreading process is called metastasis. When cancer spreads or metastasizes, it is still named after the part of the body where it started. For example, if prostate cancer spreads to the bones, it is still prostate cancer, not bone cancer. Some cancers, such as blood cancers, do not form a tumor. Not all tumors are cancer. A tumor that is not cancer is called benign and does not grow and spread the way cancer does.Close


CEA

The carcinoembryonic antigen (CEA) is present on 70 percent of lung cancers, virtually all cases of colon cancer and approximately 65 percent of breast cancers.